Evidence for Lacosamide in Palliative Care
Lacosamide shows promise as an adjunctive treatment for refractory neuropathic pain in palliative care patients, with emerging evidence supporting both oral and subcutaneous administration, though it is not currently included in established cancer pain guidelines.
Current Guideline Framework
The National Comprehensive Cancer Network (NCCN) guidelines for adult cancer pain establish antidepressants and anticonvulsants as first-line coanalgesics for cancer-related neuropathic pain that is only partially responsive to opioids 1. However, these guidelines specifically recommend:
- Gabapentin (starting 100-300 mg nightly, titrating to 900-3600 mg daily in divided doses) 1
- Pregabalin (starting 50 mg three times daily, increasing to 100 mg three times daily, maximum 600 mg daily) 1
- Other anticonvulsant agents are acknowledged as having efficacy in non-cancer neuropathic pain but without specific recommendations 1
Lacosamide is notably absent from these established guidelines [1-2], placing it in the category of "other anticonvulsant agents" that may be considered when first-line options fail.
Emerging Evidence for Lacosamide in Palliative Care
Retrospective Palliative Care Data
The most relevant evidence comes from a 2025 retrospective chart review of 91 palliative care patients (90% with cancer) where lacosamide was used primarily for neuropathic pain 3:
- Significant improvement occurred in 35% of patients, sometimes within hours of a subcutaneous loading "test" dose 3
- 44% of recipients were in their last month of life, demonstrating use in end-stage disease 3
- 59% received subcutaneous administration, with straightforward conversion from oral to subcutaneous routes 3
- Adverse effects occurred in only 11% (10/91 patients), with 5% discontinuing treatment 3
- One mild subcutaneous site reaction occurred in 59 admixtures, resolving with dexamethasone addition 3
Efficacy in Neuropathic Pain
A 2026 randomized controlled trial comparing lacosamide to pregabalin found lacosamide significantly more effective for chronic neuropathic pain 4:
- Lacosamide reduced pain scores from 7.7 to 2.50 versus pregabalin's reduction from 7.6 to 4.27 (p < 0.001) 4
- Both drugs improved quality of life across all SF-36 domains with no significant difference between groups 4
- No serious adverse drug reactions were observed 4
However, a 2024 phenotype-stratified trial showed mixed results 5:
- Lacosamide did not demonstrate superiority in patients with the irritable nociceptor phenotype 5
- Significantly more patients were responders with NNT of 4.0 for 30% pain reduction and 5.0 for 50% pain reduction 5
- The study was prematurely closed with only 49 patients completing per-protocol analysis, limiting conclusions 5
An earlier 2009 diabetic neuropathy trial showed lacosamide 400 mg/day significantly reduced pain (p = 0.05 at endpoint, p = 0.02 over treatment period) with early-onset effects during titration 6.
Recommended Approach for Palliative Care
When to Consider Lacosamide
Consider lacosamide as a second-line or third-line option when:
- First-line anticonvulsants (gabapentin, pregabalin) have failed or are not tolerated 1, 3
- Rapid pain relief is needed, as effects may appear within hours of loading doses 3
- Oral route is compromised or lost, as subcutaneous administration is feasible 3
- Patient is in advanced disease stages, including last month of life 3
Dosing Strategy
Based on the diabetic neuropathy trial and palliative care experience 3, 6:
- Oral dosing: Start 50 mg twice daily, increase to 100 mg twice daily after 1 week, target dose 400 mg/day (200 mg twice daily) 4, 6
- Subcutaneous "test" dose: Consider a loading dose to assess rapid response in palliative patients 3
- Subcutaneous maintenance: 1:1 conversion from oral appears feasible based on palliative care experience 3
- Maximum studied dose: 600 mg/day, though 400 mg/day appears optimal for efficacy-to-tolerability ratio 6
Monitoring and Efficacy Assessment
Evaluate response within the first week 3, 6:
- Early responders may show improvement within hours to days of initiation, particularly with subcutaneous loading 3
- Target pain reduction: Aim for ≥30% reduction in pain scores (NNT 4.0) or ≥50% reduction (NNT 5.0) 5
- Monitor for adverse effects: Dizziness, nausea, and headache are most common 6
- Subcutaneous site reactions: Add dexamethasone to admixture if mild reactions occur 3
Important Caveats
Lacosamide has significant limitations in the palliative care context:
- Not included in established cancer pain guidelines, unlike gabapentin and pregabalin [1-2]
- Higher cost due to twice-daily dosing compared to alternatives 4
- Limited high-quality evidence specifically in cancer-related neuropathic pain 3
- Variable response rates: Only 35% showed significant improvement in palliative care cohort 3
- Phenotype prediction unsuccessful: Cannot reliably predict which patients will respond 5
The trial-and-error nature of coanalgesic therapy means patient education should emphasize that lacosamide may or may not work, and doses should be titrated until analgesic effect is achieved, side effects become unmanageable, or maximum dose is reached 1.
Practical Algorithm
- First-line: Trial gabapentin or pregabalin per NCCN guidelines 1
- If inadequate response: Consider switching to alternative first-line agent or adding tricyclic antidepressant 7
- If first-line combinations fail: Consider lacosamide, particularly if oral route is compromised or rapid assessment needed 3
- Initiate lacosamide: 50 mg PO twice daily or SC test dose 3, 4
- Assess within 1 week: If no response or intolerable effects, discontinue; if partial response, increase to 100 mg twice daily 3, 6
- Target maintenance: 400 mg/day (200 mg twice daily) 4, 6
- SC conversion: If oral route lost, convert 1:1 to subcutaneous administration 3
The subcutaneous route represents a unique advantage in palliative care when patients lose the ability to swallow, as this option is not available with gabapentin or pregabalin 3.